Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: T12S 99% (conv=1,013) • I15V 98% (conv=1,164) • L19I 99% (conv=1,195) • M36V 100% (conv=1,288) • R41K 100% (conv=1,347) • H69K 100% (conv=2,033) • T74S 99% (conv=2,617) • L89M 100% (conv=2,685) • I93L 100% (conv=2,952)

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

PR comments

Other

- **T74S** is a PI-selected accessory mutation that is polymorphic in most non-B subtypes.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: M184V 99% (conv=1,207)
NNRTI Mutations: Y188L 100% (conv=1,287)
RT Other Mutations: E6K 100% (conv=2,901) • V35T 100% (conv=2,858) • E40D 100% (conv=2,957) • K49R 100% (conv=2,956) • V60I 100% (conv=2,756) • K122E 100% (conv=2,790) • D123N 100% (conv=2,790) • K166T 100% (conv=3,035) • Q174K 100% (conv=3,045) • D177E 100% (conv=3,253) • I178M 100% (conv=3,233) • T200A 100% (conv=3,564) • Q207E 100% (conv=3,562) • R211K 100% (conv=3,035) • V245K 100% (conv=3,410) • D250E 99% (conv=2,963)

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Low-Level Resistance
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Potential Low-Level Resistance
emtricitabine (FTC)	High-Level Resistance
lamivudine (3TC)	High-Level Resistance
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	High-Level Resistance
efavirenz (EFV)	High-Level Resistance
etravirine (ETR)	Potential Low-Level Resistance
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	High-Level Resistance

RT comments

NRTI

- **M184V/I** cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). **M184V/I** are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

NNRTI

- **Y188L** is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI: Download CSV

Rule	ABC	AZT	D4T	DDI	FTC	3TC	TDF
M184V	15	-10	-10	10	60	60	-10

Drug resistance mutation scores of NNRTI: Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
Y188L	60	60	10	60	60

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: V31I 100% (conv=54) • M50V 100% (conv=70) • K136Q 100% (conv=62)

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.